Frontotemporal lobar degeneration

Area of Science:

• Neuroscience
• Genetics
• Pathology

Background:

• Frontotemporal lobar degeneration (FTLD) is a leading cause of early-onset dementia.
• FTLD is characterized by social-emotional-behavioral and/or language changes, potentially with motor disorders.
• Approximately 20-25% of FTLD cases are linked to specific genetic mutations.

Purpose of the Study:

• To review advances in understanding FTLD genetics and pathology.
• To highlight the challenges and progress in developing diagnostic biomarkers for sporadic FTLD.
• To discuss the potential of novel therapeutic strategies for FTLD.

Main Methods:

• Review of current literature on FTLD genetics, pathology, and biomarkers.
• Analysis of the role of tau, TDP-43, and FUS protein inclusions in FTLD subtypes.
• Examination of emerging diagnostic and therapeutic approaches.

Main Results:

• FTLD subtypes include FTLD-tau, FTLD-TDP, and FTLD-FET.
• Genetic mutations have improved understanding and treatment development for FTLD.
• Definitive biomarkers for sporadic FTLD pathology remain elusive, hindering treatment development.

Conclusions:

• Sophisticated biofluid and imaging biomarkers are advancing disease monitoring and treatment response assessment.
• Novel symptomatic treatments, such as transcranial direct current stimulation, show promise.
• Continued research into FTLD genetics, pathology, and biomarkers is essential for effective disease modification.